The rise and fall of IBM Watson Health represents one of the most instructive case studies in the history of enterprise computing, digital health, and clinical informatics. Marketed as a revolutionary breakthrough that would eliminate diagnostic errors and personalise oncology care globally, the enterprise culminated in a multi-billion-dollar strategic retreat, the cancellation of flagship academic partnerships, and the eventual liquidation of its assets. The collapse was no

The Hilo blood pressure monitoring platform represents a pivotal technological advancement in continuous, non-invasive cardiovascular surveillance. Originally established in Neuchâtel, Switzerland, as Aktiia SA, the enterprise emerged from nearly two decades of dedicated micro-engineering research conducted at the Swiss Center for Electronics and Microtechnology (CSEM). Co-founded by Mattia Bertschi and Josep Sola, the organisation pioneered optical pulse wave analysis to der

The global healthcare technology (HealthTech) and medical technology (MedTech) mergers and acquisitions ecosystem in August 2026 operates under a regime defined by institutional market participants as "HealthTech 2.0" or "Industrial Maturity". Moving past the venture subsidised capital deployment of the post-pandemic era and the severe valuation compression experienced during 2022–2023, current market mechanics demonstrate disciplined capital allocation, rigorous underwriting

For European health companies operating in the mid-market segment, defined as those with enterprise values (EV) between €25M and €250M, the initial public offering (IPO) window is structurally closed. Public equity markets have fundamentally recalibrated their underwriting criteria, demanding institutional scale, positive EBITDA and deep secondary market liquidity that companies within this valuation band cannot credibly deliver.

The rapid decay of foundation model inference costs, paired with the proliferation of high-performing open-source architectures, has initiated a deflationary wave across the software landscape. In healthcare technology, where software historically commanded premium valuation multiples due to high switching costs and regulatory moats, this shift has exposed a structural divide. The market no longer awards a generalized "AI premium" to applications that merely expose a thin use

The European healthcare technology and medical device ecosystem has entered an era of disciplined maturity. The speculative valuation inflation of the early 2020s has given way to a metrics-driven environment where strategic value is defined by clinical utility, regulatory resilience and technological defensibility. Within this landscape, European founders face a structural reality: domestic exit options are frequently constrained by fragmented national healthcare systems, lo

Average HealthTech deal size has more than tripled since 2022, but the entry multiples that make a fund's vintage are still found below €250M EV. Global and European healthcare M&A surged in 2025, with global transaction value reaching $546.7 billion, a 38% increase year-over-year. In Europe, private equity healthcare buyout value reached $80.9 billion in 2025 and is projected to surpass $95.0 billion in 2026. Disclosed global healthcare buyout value exceeded $191 billion in

Unlike physical clinic branches, clinical software assets cannot exist as autonomous, siloed outposts under a shared corporate umbrella. Digital health assets operate within highly complex, tightly coupled clinical workflows, heterogeneous data environments, and stringently enforced regulatory frameworks. When acquired software assets fail to integrate at the codebase, data schema, and quality management levels, expected cost and revenue synergies evaporate. Instead, platform

By the time a subsector has a Kearney report, the entry multiple has already moved. Here's what's crossing our desk now. The macroeconomic landscape for European healthcare technology has undergone a structural transformation. The speculative capital deployment into unintegrated point solutions that characterised the zero-interest-rate era has given way to an environment focused on unit economics, real-world clinical evidence, regulatory defensibility and deep workflow integr

The National Health Service (NHS) in England is undertaking a structural transformation anchored by the 10 Year Health Plan, titled Fit for the Future. This strategy addresses the compounding pressures of an aging population, rising multimorbidity, and unsustainable demand on acute hospital infrastructure by instituting three fundamental shifts: moving care from hospital to community, transitioning from analogue to digital operations, and pivoting from reactive sickness manag

This financial environment has laid the groundwork for geographic arbitrage across European mid-market private equity. While London historically commanded a disproportionate share of early-stage venture funding, institutional investors seeking scalable buy-and-build platform deals are increasingly looking to the DACH region (Germany, Austria, Switzerland), the Nordic countries and the Netherlands.

In a milestone transaction within the European healthcare technology sector, software private equity firm Thoma Bravo announced and finalised its strategic growth investment in padoa, acquiring a majority stake in the European leader in occupational health, safety, and prevention software. The transaction, executed through the €1.8 billion Thoma Bravo Europe Fund, represents a notable expansion of the firm’s dedicated buyout strategy across core European software markets.

Abbott Laboratories has established a distinctive operational blueprint for artificial intelligence deployment within the healthcare and medical technology sectors. Rather than treating emerging technology as a speculative end in itself, Abbott anchors every algorithmic, generative, and agentic capability directly to its core corporate mission of helping individuals live healthier, fuller lives. Under the leadership of Chief Information Officer and Senior Vice President of Bu

This Week in European HealthTech, MedTech and Health AI: 31st July 2026. Here is a breakdown of the major developments driving the European HealthTech ecosystem right now:

The rapid expansion of screenless wearables has positioned smart rings as a primary form factor for continuous, unobtrusive biometric monitoring. Market leader Oura Health has long established the functional benchmark for ring-based photoplethysmography (PPG), circadian rhythm tracking, and daily recovery analysis. However, the emergence of challengers such as the British-designed Leep Ring, developed by Leep Health Ltd, raises a fundamental architectural and strategic questi